Live Breaking News & Updates on Single Arm Study

Stay updated with breaking news from Single arm study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Beirut , Beyrouth , Lebanon , Spain , Cambridge , Cambridgeshire , United-kingdom , Boston , Massachusetts , United-states , Canada , Rio-de-janeiro

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients ....

San-antonio , Texas , United-states , American , Calmette-guerin , Laurence-watts , Markd-tyson , Cretostimogene-grenadenorepvec , Henryb-gonz , Intravesical-cretostimogene-grenadenorepvec , Globe-newswire-cg-oncology-inc , Convention-center

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients ....

United-states , San-antonio , Texas , University-of-texas , America , American , Intravesical-cretostimogene-grenadenorepvec , Calmette-guerin , Cretostimogene-grenadenorepvec , Ambaw-bellete , Henryb-gonz , Bing-kung

Key Takeaways from Phase 4 Switch Trial Presented at AAO

Richard Adler, MD, FACS, discusses the Switch trial which compared OTX-101 (cyclosporine ophthalmic solution 0.09%) vs cyclosporine ophthalmic emulsion 0.05% (Restasis) in patients with dry eye disease (DED). ....

Managing-dry-eye-disease , Trial-presented , Cequa , Open-label , Single-arm-study , Incomplete-response , Restasis , Dry-eye-disease , Corneal-staining , Sande-score , Symptom-assessment-questionnaire-in-dry-eye-corneal-staining